EGFR and non-small cell lung carcinoma: Sunvozertinib (DZD9008; Zegfrovy®; Dizal Pharma) is a next-generation oral EGFR TKI, that has been in development primarily for the treatment of NSCLC harboring EGFR exon 20 insertion mutations (EGFR Ex20Ins), a subset of EGFR alterations that are notoriously resistant to first- and second-generation EGFR inhibitors, leading to scarce treatment options.